Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Iveric Bio Inc (NQ: ISEE )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 10, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Iveric Bio Inc

< Previous 1 2 3 4 Next >
IVERIC bio Inc. (NASDAQ: ISEE) Records 52-Week High Thursday Morning
Via Investor Brand Network
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From IVERIC bio, Inc.
Via Business Wire
IVERIC BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of IVERIC bio, Inc. - ISEE
From Kahn Swick & Foti, LLC
Via Business Wire
IVERIC bio Inc. (NASDAQ: ISEE) Making Surprising Moves in Monday Session
Via Investor Brand Network
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From IVERIC bio, Inc.
Via Business Wire
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
By David Willey, Benzinga 
Via TheNewswire.com
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From IVERIC bio, Inc.
Via Business Wire
IVERIC BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of IVERIC bio, Inc. - ISEE
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Iveric Bio Inc. (Nasdaq – ISEE), Midwest Holding Inc. (Nasdaq – MDWT), Hoth Therapeutics, Inc. (Nasdaq – HOTH)
From Brodsky & Smith LLC
Via GlobeNewswire
ISEE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Iveric bio, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Astellas Enters Into Definitive Agreement to Acquire Iveric Bio
From IVERIC Bio, Inc.
Via Business Wire
Iveric Bio Announces New Functional Vision Loss Reduction Data from Avacincaptad Pegol GATHER Trials Presented at ARVO Annual Meeting
From IVERIC bio, Inc.
Via Business Wire
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From IVERIC bio, Inc.
Via Business Wire
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From IVERIC bio, Inc.
Via Business Wire
Iveric Bio Reports Fourth Quarter and Full Year 2022 Operational Highlights and Financial Results
From IVERIC bio, Inc.
Via Business Wire
Iveric Bio Announces Vision Loss Reduction Data in Geographic Atrophy from Avacincaptad Pegol GATHER Trials
From Iveric Bio
Via Business Wire
Iveric Bio to Present at the Cowen 43rd Annual Health Care Conference
From IVERIC bio, Inc.
Via Business Wire
Iveric Bio to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on Wednesday, March 1, 2023
From IVERIC bio, Inc.
Via Business Wire
Iveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic Atrophy
From IVERIC bio, Inc.
Via Business Wire
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From IVERIC bio, Inc.
Via Business Wire
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From IVERIC bio, Inc.
Via Business Wire
Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors
From IVERIC bio, Inc.
Via Business Wire
Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy
From Iveric bio, Inc.
Via Business Wire
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From IVERIC bio, Inc.
Via Business Wire
Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock
From IVERIC bio, Inc.
Via Business Wire
Iveric Bio Announces Proposed Offering of Common Stock
From IVERIC bio, Inc.
Via Business Wire
Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy
From IVERIC bio, Inc.
Via Business Wire
Iveric Bio to Present at Upcoming Investor Conferences
From Iveric Bio
Via Business Wire
Iveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy
From IVERIC bio, Inc.
Via Business Wire
Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results
From IVERIC bio, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.